Zafgen, the Cambridge, MA-based developer of drugs to shrink fat tissue, said today it has formed a partnership with Harlow, UK-based Argenta Discovery. Argenta, a contract research firm, will assist with the development of one of Zafgen’s experimental treatments for obesity. Earlier this week, we profiled this company’s quest to pioneer a new method of treatment which cuts off blood flow to fat tissue. Financial terms of the new partnership weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
